高级检索
当前位置: 首页 > 详情页

Therapeutic effects of mifepristone combined with Gestrinone on patients with endometriosis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Univ, Affiliated Hosp, Dept Obstet & Gynecol, Baoding 071000, Hebei Province, Peoples R China [2]Peoples Hosp Yi Cty, Dept Obstet & Gynecol, Baoding 074200, Hebei Province, Peoples R China
出处:
ISSN:

关键词: Endometriosis Gestrinone Mifepristone

摘要:
Objective: To evaluate the clinical therapeutic effects of mifepristone combined with gestrinone on patients with endometriosis. Methods: A total of 150 endometriotic patients treated in our hospital between January 2014 and December 2015 were randomly divided into a control group and a treatment group (n=75). The control group began to orally take gestrinone capsules on the second day after menstruation started (2.5 mg/time, twice/week). The treatment group orally took mifepristone tablets (12.5 mg/time, once/day), and the dosage and administration of gestrinone capsules were the same as those of the control group. After 24 weeks of consecutive treatment, the clinical therapeutic effects of the two groups were assessed, and the pelvic symptom score, clinical sign score, serum sex hormone levels and pregnancy outcomes were compared. Results: The total effective rates of control and treatment groups were 77.3% and 90.7% respectively, between which the difference was statistically significant (P<0.05). After treatment, the scores of pelvic symptoms (dysmenorrhea, dyspareunia, pelvic pain) and clinical signs (pelvic tenderness, induration) significantly reduced (P<0.05). Each score of the treatment group decreased more significantly than that of the control group did (P<0.05). The serum follicle hormone, luteinizing hormone, estrogen and progesterone levels were significantly lower than those before treatment (P<0.05). Each level of the treatment group dropped more significantly than that of the control group did (P<0.05). The pregnancy rates in the 6th and 12th months of follow-up were 28.0% and 13.3% in the control group respectively, and 42.7% and 29.3% in the treatment group respectively. Such rates of the two groups were significantly different at each followup time point (P<0.05). Conclusion: Mifepristone combined with gestrinone had satisfactory clinical therapeutic effects on endometriosis by reducing hormone levels and improving pregnancy outcomes. Therefore, this regimen is worthy of promotion and application in clinical practice.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2016]版:
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Hebei Univ, Affiliated Hosp, Dept Obstet & Gynecol, Baoding 071000, Hebei Province, Peoples R China [2]Peoples Hosp Yi Cty, Dept Obstet & Gynecol, Baoding 074200, Hebei Province, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15101 今日访问量:1 总访问量:961 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号